

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10580999
Filing Date	2007-03-12
First Named Inventor	Ljubimova, Julia Y.
Art Unit	1633
Examiner Name	EPPS-SMITH, JANET L.
Attorney Docket Number	67789-118US0

<b>U.S.PATENTS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						<b>Add</b>		
<b>U.S.PATENT APPLICATION PUBLICATIONS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020155440		2002-10-24	Black et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.						<b>Add</b>		
<b>FOREIGN PATENT DOCUMENTS</b>						<b>Remove</b>		
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2005/028617	WO	A2	2005-03-31	Arrogene, Inc.		<input type="checkbox"/>
	2	2002/059610	WO	A2	2002-08-01	Cedars-Sinai Medical Center		<input type="checkbox"/>
	3	2001/087239	WO	A2	2001-11-22	Fibrogen, Inc.		<input type="checkbox"/>

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10580999
	Filing Date	2007-03-12
	First Named Inventor	Ljubimova, Julia Y.
	Art Unit	1633
	Examiner Name	EPPS-SMITH, JANET L.
	Attorney Docket Number	67789-118US0

If you wish to add additional Foreign Patent Document citation information please click the Add button <input type="button" value="Add"/>		
<b>NON-PATENT LITERATURE DOCUMENTS</b>		<input type="button" value="Remove"/>
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.
	1	ABDELLAOUI et al., Metabolite-derived Artificial Polymers Designed for Drug Targeting, Cell Penetration and Bioresorption, European Journal of Pharmaceutical Sciences, Volume 6, No. 1 (1998), pages 61-73 <input type="checkbox"/>
	2	BARBOSA, et al., Investigation of the Degradation Mechanisms of Poly(malic acid) Esters in Vitro and their Related Cytotoxicities on J774 Macrophages, Biomacromolecules 2004, Volume 5, No. 1, pages 137-143 <input type="checkbox"/>
	3	QIAN et al., Targeted Drug Delivery via the Transferrin Receptor-mediated Endocytosis Pathway, Pharmacology Reviews, Volume 54, No. 4, (Dec. 2002), pages 561-587 <input type="checkbox"/>
	4	ZHANG et al., Antisense Gene Therapy of Brain Cancer with an Artificial Virus Gene Delivery System, Molecular Therapy, Volume 6, No. 1 (July 2002), pages 67-72 <input type="checkbox"/>
	5	LJUBIMOVA, J. et al., Changes in Laminin Isoforms Associated with Brain Tumor Invasion and Angiogenesis, Frontiers in Bioscience (Jan. 1, 2006), Vol. 11, pages 81-88 <input type="checkbox"/>
	6	LJUBIMOVA, J., Black, K., Holler, E., Development of Anti-Angiogenic and Anti-Invasive Inhibitors of Human Gliomas Using a New Multifunctional Drug Delivery System Based on Polymalic Acid, Preclinica (Sept./Oct. 2004), 2(5), p. 366 <input type="checkbox"/>
	7	LJUBIMOVA, J. et al., Association between Laminin-8 and Glial Tumor Grade, Recurrence, and Patient Survival, Cancer (online Jun. 16, 2004), 101(3), pages 604-12 <input type="checkbox"/>
	8	NAGATO, et al., Downregulation of Laminin $\alpha$ -4 Chain Expression Inhibits Glioma Invasion in vitro and in vivo, Int. Journal of Cancer (Oct. 20, 2005), 117(1), pages 41-50 <input type="checkbox"/>
	9	FUKUSHIMA et al., Integrin $\alpha 3\beta 1$ -mediated Interaction with Laminin-5 Stimulates Adhesion, Migration and Invasion of Malignant Glioma Cells, Int. of Journal Cancer (Mar. 30, 1998), 76(1), pages 63-72 <input type="checkbox"/>
If you wish to add additional non-patent literature document citation information please click the Add button <input type="button" value="Add"/>		

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <b>( Not for submission under 37 CFR 1.99)</b>	Application Number	10580999
	Filing Date	2007-03-12
	First Named Inventor	Ljubimova, Julia Y.
	Art Unit	1633
	Examiner Name	EPPS-SMITH, JANET L.
	Attorney Docket Number	67789-118US0

### EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.